CytoDyn
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Washington, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1111 Main St Ste 660, Vancouver, Washing...Phone Number
(360) 980-8524Website
www.cytodyn.comRevenue
-Stock Symbol
CYDYIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
1
1
1
1
1
About CytoDyn
CytoDyn Inc. is a U.S.-based, publicly traded clinical-stage biotechnology company focused on developing innovative therapies for serious diseases, particularly in oncology and immunology. Founded in 2002 and headquartered in Vancouver, Washington, the company operates within the healthcare and biotechnology sector. The companys core focus is the development of leronlimab, a novel humanized monoclonal antibody that targets the CCR5 receptora key regulator of immune function involved in cancer progression, inflammation, and certain infectious diseases. Leronlimab is being studied as a potential treatment across multiple indications, with a strong emphasis on solid-tumor oncology, including metastatic colorectal cancer and triple-negative breast cancer.Explore more
CytoDyn Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is CytoDyn your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if CytoDyn has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once CytoDyn has new funding data
Product Launch: Get notified when CytoDyn launches new products
Earning: See what the market has to say on CytoDyn recently announced quarterly report
CytoDyn, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if CytoDyn is spiking on competitors!
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if CytoDyn had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at CytoDyn
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to CytoDyn
Compare insights from companies similar to CytoDyn, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
CytoDyn is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
CytoDyn is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about CytoDyn.
CytoDyn financials insights
Gather financial insights about CytoDyn, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Debt
$1.1M
2019
Share Placement
$12M
2020
Debt
$15M
Debt
$2.5M
2021
Debt
$25M
2026
Unspecified
$17.5M
Unspecified
$16.5M
CytoDyn Tech Stack
A closer look at the technologies used by CytoDyn
Most Recent Scoops
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Funding
Funding
Person-Based
CytoDyn News & Media
CytoDyn Closes $16.5 Million Financing to Fund Continued Development of Leronlimab
VANCOUVER, Washington, Sept. 01, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including triple-negative breast cancer (TNBC) and metastatic colorectal cancer (mCRC), today announced that it has closed on a financing of $16.5 million in gross proceeds, with Paulson InvestmentExpanded Access And Rollover Design Help CytoDyn Reach High-Need Cancer Patients
CEO Jay Lalezari and CFO Robert E. Hoffman share how CytoDyn meet patient needs when they approach trial design for cancer trials.Kessler Topaz Meltzer & Check, LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of CytoDyn Inc. common stock
TACOMA, Wash., July 22, 2026 /PRNewswire/ -- Kessler Topaz Meltzer & Check, LLP announces proposed class action settlement on behalf of purchasers of CytoDyn Inc. common stock between March 27, 2020 and March 30, 2022 (OTCQB: CYDY): UNITED STATES DISTRICT COURT WESTERN DISTRICT OF...CytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer’s Disease
Phase 2a study will evaluate the safety and biological activity of leronlimab in patients over the age of 50 with early-stage, biomarker-confirmed Alzheimer’s disease
Read more news
Top Manufacturing Companies
See more top companies
Frequently Asked Questions Regarding CytoDyn
Sign Up For FreeTo access detailed company insights
CytoDyn Inc. is a U.S.-based, publicly traded clinical-stage biotechnology company focused on developing innovative therapies for serious diseases, particularly in oncology and immunology. Founded in 2002 and headquartered in Vancouver, Washington, the company operates within the healthcare and biotechnology sector. The companys core focus is the d... Read More
